First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer

  • Claus-Henning KöhneEmail author
  • Ralf Hofheinz
  • Laurent Mineur
  • Henry Letocha
  • Richard Greil
  • Josef Thaler
  • Eva Fernebro
  • Erick Gamelin
  • Lucy DeCosta
  • Meinolf Karthaus
Original Paper



Panitumumab monotherapy is approved for KRAS wild-type (WT) metastatic colorectal cancer (mCRC) progressing after standard chemotherapy. This study evaluated first-line panitumumab plus FOLFIRI in patients with mCRC.


In this phase II, single-arm study, panitumumab (6 mg/kg) and FOLFIRI [irinotecan (180 mg/m2) and leucovorin (400 mg/m2) followed by a 5-fluorouracil 400 mg/m2 bolus and a 2,400–3,000 mg/m2 continuous infusion] were administered every 14 days until progression. Data were analysed descriptively overall and by tumour KRAS status.


KRAS data were available for 145/154 (94%) patients: 59% KRAS WT and 41% mutant (MT); mean follow-up was 39.5 versus 35.8 weeks, respectively. Objective responses occurred in 49% of patients: 56% versus 38% in the KRAS WT versus MT groups [(18% difference (95% CI 1–35%); odds ratio 2.1 (95% CI 1.0–4.4)]; median duration of response was 13.0 versus 7.4 months. More patients in the WT group underwent R0 resection (8% vs. 5%); median progression-free survival also favoured this group (8.9 vs. 7.2 months). The most common adverse events (any grade) were integument toxicities (98%), diarrhoea (79%) and stomatitis/oral mucositis (51%).


As expected, consistently favourable efficacy was observed in patients with KRAS WT versus MT tumours receiving first-line panitumumab plus FOLFIRI treatment.


Chemotherapy Fully human monoclonal antibody Metastatic colorectal cancer Panitumumab 



This work was supported by Amgen (Europe) GmbH, Zug, Switzerland. Medical writing support [funded by Amgen (Europe) GmbH] provided by Dawn Batty (Bioscript Stirling Ltd); manuscript preparation assistance provided by Emma Thomas (Amgen). Pamela Ward and David Eaton: study management; Marco Schupp: study design/initiation; Karin Blakolmer: critical review of the data/manuscript (all Amgen employees).

Conflict of interest

CHK has acted as a consultant/advisor to Amgen Ltd, Merck KG Damstadt & Roche Ltd; HL has acted as a consultant/advisor for Amgen Ltd & Roche Ltd; RH, JT & MK have received honoraria from Amgen Ltd, JT has also received research funding and MK has also acted as an advisor for this company; EG & LDC are employees of Amgen Ltd and also own shares in this company.

Supplementary material

432_2011_1061_MOESM1_ESM.pdf (58 kb)
Supplementary material 1 (PDF 58 kb)


  1. Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634. doi: 10.1200/JCO.2007.14.7116 PubMedCrossRefGoogle Scholar
  2. Amgen Inc (2010) Vectibix® prescribing information
  3. Amgen Ltd (2009) Vectibix® (panitumumab) summary of product characteristics
  4. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643–2648. doi: 10.1158/0008-5472.CAN-06-4158 PubMedCrossRefGoogle Scholar
  5. Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671. doi: 10.1200/JCO.2008.20.8397 PubMedCrossRefGoogle Scholar
  6. Cohenuram M, Saif MW (2007) Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18:7–15. doi: 10.1097/CAD.0b013e32800feecb PubMedCrossRefGoogle Scholar
  7. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345. doi: 10.1056/NEJMoa033025 PubMedCrossRefGoogle Scholar
  8. De Roock W, Piessevaux H, De Schutter J et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508–515. doi: 10.1093/annonc/mdm496 PubMedCrossRefGoogle Scholar
  9. Di Fiore F, Blanchard F, Charbonnier F et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96:1166–1169. doi: 10.1038/sj.bjc.6604451 PubMedCrossRefGoogle Scholar
  10. Dolgin E (2009) FDA narrows drug label usage. Nature 460:1069. doi: 10.1038/4601069a PubMedCrossRefGoogle Scholar
  11. Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047. doi: 10.1016/S0140-6736(00)02034-1 PubMedCrossRefGoogle Scholar
  12. Douillard JY, Siena S, Cassidy J et al (2010) Randomized, phase 3 study (PRIME) of panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 28:4697–4705. doi: 10.1200/JCO.2009.27.4860 PubMedCrossRefGoogle Scholar
  13. European Medicines Agency (2009a) Erbitux® (cetuximab) prescribing information
  14. European Medicines Agency (2009b) Vectibix® (panitumumab) prescribing information
  15. European Medicines Agency (2011) Committee for Medicinal Products for Human Use (CHMP). Summary of opininin (post-authorisation)—Vectibix (panitumumab) 2011
  16. Freeman DJ, Juan T, Reiner M et al (2008) Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7:184–190. doi: 10.3816/CCC.2008.n.024 PubMedCrossRefGoogle Scholar
  17. Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol 25:4779–4786. doi: 10.1200/JCO.2007.11.3357 PubMedCrossRefGoogle Scholar
  18. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342. doi: 10.1056/NEJMoa032691 PubMedCrossRefGoogle Scholar
  19. Kari C, Chan TO, Rocha de Quadros M, Rodeck U (2003) Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res 63:1–5PubMedGoogle Scholar
  20. Koo DH, Lee JL, Kim TW et al (2007) A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. J Korean Med Sci 22(Suppl):S98–S103PubMedCrossRefGoogle Scholar
  21. Lièvre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995PubMedCrossRefGoogle Scholar
  22. National Cancer Institute Cancer Therapy Evaluation Program [CTEP] (2005) Common toxicity criteria for adverse events v3.0 (CTCAE)
  23. National Cancer Institute Cancer Therapy Evaluation Program [CTEP] (2006) Common terminology criteria for adverse events (CTCAE), Version 3.0, DCTD, NCI, NIH, DHHS
  24. Peeters M, Price T, Cervantes A et al (2010) Randomized phase 3 study of panitumumab with FOLFIRI versus FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706–4713PubMedCrossRefGoogle Scholar
  25. Raoul JL, Van Laethem JL, Peeters M et al (2009) Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer 9:112. doi: 10.1186/1471-2407-9-112 PubMedCrossRefGoogle Scholar
  26. Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905–914PubMedCrossRefGoogle Scholar
  27. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201–1208. doi: 10.1200/JCO.2004.10.182 PubMedCrossRefGoogle Scholar
  28. Santini D, Loupakis F, Vincenzi B et al (2008) High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 13:1270–1275. doi: 10.1634/theoncologist.2008-0181 PubMedCrossRefGoogle Scholar
  29. Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425–1433. doi: 10.1093/annonc/mdi279 PubMedCrossRefGoogle Scholar
  30. Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319. doi: 10.1200/JCO.2007.13.1193 PubMedCrossRefGoogle Scholar
  31. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216. doi: 10.1093/jnci/92.3.205 PubMedCrossRefGoogle Scholar
  32. Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229–237. doi: 10.1200/JCO.2004.05.113 PubMedCrossRefGoogle Scholar
  33. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664. doi: 10.1200/JCO.2006.08.1620 PubMedCrossRefGoogle Scholar
  34. Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417. doi: 10.1056/NEJMoa0805019 PubMedCrossRefGoogle Scholar
  35. Yen LC, Yeh YS, Chen CW et al (2009) Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 15:4508–4513. doi: 10.1158/1078-0432.CCR-08-3179 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Claus-Henning Köhne
    • 1
    Email author
  • Ralf Hofheinz
    • 2
  • Laurent Mineur
    • 3
  • Henry Letocha
    • 4
  • Richard Greil
    • 5
  • Josef Thaler
    • 6
  • Eva Fernebro
    • 7
  • Erick Gamelin
    • 8
  • Lucy DeCosta
    • 9
  • Meinolf Karthaus
    • 10
    • 11
  1. 1.Department of Hematology and OncologyOnkologie Klinikum OldenburgOldenburgGermany
  2. 2.Day Treatment Centre at the Interdisciplinary Tumour Centre MannheimUniversitätsmedizin MannheimMannheimGermany
  3. 3.Radiology and Oncology CentreInstitut Sainte-CatherineAvignonFrance
  4. 4.Department of OncologyCounty HospitalVästeråsSweden
  5. 5.Third Medical DepartmentUniversity Hospital SalzburgSalzburgAustria
  6. 6.Department of Hematology and Medical OncologyKlinikum Wels-GrieskirchenWelsAustria
  7. 7.Department of OncologyUniversity HospitalLundSweden
  8. 8.Department of Medical Oncology and OncopharmacologyCentre Paul PapinAngersFrance
  9. 9.Biostatistics, Amgen LimitedUxbridgeUK
  10. 10.Department of Hematology, Oncology and Palliative MedicineKlinikum NeuperlachMunichGermany
  11. 11.Department of Hematology, Oncology and Palliative MedicineKlinikum HarlachingMunichGermany

Personalised recommendations